Masters of Longevity - The Pulse

Fight Aging!27 Jul 2026
AIEffects of Clonal Haematopoiesis of Indeterminate Potential on Epigenetic Age (Fight Aging!)

Effects of Clonal Haematopoiesis of Indeterminate Potential on Epigenetic Age

Review and meta-analysis examining links between clonal hematopoiesis and DNA methylation clocks, comparing epigenetic age across CHIP and non-CHIP groups.

Key takeaways
  • Is a form of somatic mosaicism in the immune system.
  • While the research community largely agrees that DNA damage is important in aging.
  • CHIP individuals had higher EAA than no-CHIP individuals.
Longevity Technology27 Jul 2026
AIAnHorn Medicines begins Phase 1 trial for new drug to prevent chemotherapy-related nerve damage (Longevity Technology)

AnHorn Medicines begins Phase 1 trial for new drug to prevent chemotherapy-related nerve damage

A news item announcing a clinical research update on a new preventative therapy for chemotherapy-related nerve damage, useful for readers tracking drug development and translational neurology.

Key takeaways
  • We are open to conversations with prospective partners and investors who share our vision.
  • First-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy.
  • Notes that no approved preventive therapies currently exist.
MoL Event Pick
MedTech World Asia | Hong Kong 2026 (Hong Kong, Hong Kong)

MedTech World Asia | Hong Kong 2026

26. AUG 2026 - 28. AUG 2026 - Hong Kong, Hong KongSummit

Hong Kong summit connecting MedTech and HealthTech leaders, startups, investors, hospital executives, regulators and innovators across APAC healthcare innovation.

Nature - Biotechnology27 Jul 2026
AIAn agent-guided peptide hydrogel bio-stabilizer clamps pericellular viscoelastic drift (Nature - Biotechnology)

An agent-guided peptide hydrogel bio-stabilizer clamps pericellular viscoelastic drift

Covers a materials strategy that stabilizes pericellular viscoelastic mechanics using an engineered peptide hydrogel to reduce glycation-driven mechanical drift and support tissue repair.

Key takeaways
  • This work was supported by the National Key R&D Program of China (2024YFC2418700).
  • Please note there may be errors present which affect the content, and all legal disclaimers apply.
  • We show that ViscoClamp buffers chronic glycation loading and constrains glycation-driven viscoelastic drift.
Longevity Technology27 Jul 2026
AISerina advances Parkinson’s drug candidate, versatile drug delivery tech (Longevity Technology)

Serina advances Parkinson’s drug candidate, versatile drug delivery tech

Serina’s development updates on a polymer drug-delivery platform and a Parkinson’s therapy candidate, plus the company’s upcoming investor outreach.

Key takeaways
  • Serina Therapeutics will participate in the BTIG Virtual Biotechnology Conference on 28-29 July 2026.
  • POZ-apomorphine candidate intended to provide continuous dopaminergic stimulation for Parkinson’s disease.
  • Serina is a clinical-stage biotechnology company listed on NYSE American under SER and is headquartered in Huntsville.